Adjuvant therapy in renal cell carcinoma-is pharmacogenomics assessment another element to select our patients?

Abstract

Adjuvant therapy in resected renal cell carcinoma (RCC) is a discussed and complex issue due to conflicting results obtained in several clinical trials exploring different agents in this setting (1-4).